• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skin Care
  • Ask the Expert

DermaTalk

Lets Talk about your Skin

  • Home
  • Beauty and Make Up
  • Disease and Condition
    • acne
    • Nail Disorder
    • Skin cancer
    • Viral Infection
    • Psoriasis
  • HEALTHY LIVING
  • Anti Aging
  • Cosmetic Surgery
  • Product Reviews
  • Genital Dermatology
You are here: Home / Skin Disorders / Skin cancer / New Drug For Skin Cancer Approaching Commercialization

New Drug For Skin Cancer Approaching Commercialization

December 7, 2008 by Dr.Deepak Leave a Comment

A drug that is activated by light can be a quick, simple, and cheap treatment for tens of thousands of patients with skin cancer in Sweden alone. Researcher Leif Eriksson’s team at Örebro University in Sweden has now received about SEK 4 million from government research financiers, the Swedish Research Council and Vinnova, to further develop and commercialize the method.

The new drug that the Örebro researchers have developed is based on the use of photo-dynamic therapy in cancer treatment. In short, this is a drug that after reorganization in the cell is activated by light, which in turn leads to chemical reactions that effectively kills cancer cells.

With this method, a majority of the some 30,000 new cases of skin cancer discovered each year in Sweden alone could be treated quickly, simply, and cost effectively. This is also true for pre-stages of skin cancer, so-called actinic keratosis.

“It’s extremely gratifying that two of the most important research financiers in Sweden so actively support our research,” says Leif Eriksson, professor of biophysical and theoretical chemistry at Örebro University.

Leif Eriksson’s drug research has grown out of the Örebro Life Science Center (OLSC), an interdisciplinary, internationally acclaimed research node at Örebro University. Research on new forms of treatment for skin tumors is also being conducted in collaboration with Associate Professor Lennart Löfgren at the Center for Head and Neck Oncology at Örebro University Hospital.

“Our drug, and the new treatment concept we are developing together with researchers in Belfast, has tremendous potential. In the coming year we will also see further patents as a direct result of the collaboration with other research teams within the OLSC, including treatments for atherosclerosis and autoimmune disorders such as rheumatism,” says Leif Eriksson.

The development of new drugs is being carried out with the aid of advanced computer modeling – a method that has proven to be highly successful.

“We provide the expertise in the theoretical description of new drugs. In our research we aim to describe at a detailed level what they should look like, what properties they should have to match the right targets in the body, what happens if we alter the molecules in different ways, etc. We then put this together through collaboration with experimental or clinically active research teams within OLSC and at the hospital, which makes the research exciting and dynamic,” says Leif Eriksson

Adapted from materials provided by Vetenskapsrådet (The Swedish Research Council), via AlphaGalileo

Filed Under: Skin cancer Tagged With: cancer, new drug for cancer, Skin cancer, Squamous Cell Carcinoma

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

skin care advice

Latest Posts

  • Home Remedies for Sweaty Armpits
  • Rash in Corner of Mouth: Angular Cheilitis and its Treatment
  • Heat rash in Babies: Best ways to Treat and Prevent
  • Minocycline Topical Foam 1.5% Approved by FDA for Rosacea
  • What is Maskne (Mask Acne): Its Treatment and Prevention

Return to top of page

About Us Contact us Privacy Policy Copyright and Terms of Use Copyright © 2021 · Skin Care Blogs by DermaTalk